Tocagen (NASDAQ:TOCA) posted its earnings results on Tuesday. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10), Fidelity Earnings reports. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million.
NASDAQ:TOCA traded down $0.04 during trading hours on Wednesday, reaching $0.60. 3,504 shares of the stock were exchanged, compared to its average volume of 410,014. Tocagen has a twelve month low of $0.53 and a twelve month high of $14.75. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.21 and a quick ratio of 4.21. The firm has a 50 day moving average of $0.64 and a 200 day moving average of $4.36. The stock has a market cap of $15.16 million, a PE ratio of -0.26 and a beta of 3.89.
TOCA has been the subject of a number of research reports. Cantor Fitzgerald reissued a “neutral” rating on shares of Tocagen in a research note on Thursday, October 17th. Citigroup cut Tocagen from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $20.00 to $1.00 in a research note on Friday, September 13th. Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Wednesday, September 18th. Robert W. Baird downgraded Tocagen from an “outperform” rating to a “neutral” rating in a research report on Thursday, September 12th. Finally, ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $10.26.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.